Oppenheimer Maintains Outperform on Sage Therapeutics, Lowers Price Target to $84
Oppenheimer analyst Jay Olson maintains Sage Therapeutics (NASDAQ:SAGE) with a Outperform and lowers the price target from $100 to $84.
Needham Maintains Buy on Sage Therapeutics, Lowers Price Target to $79
Needham analyst Ami Fadia maintains Sage Therapeutics (NASDAQ:SAGE) with a Buy and lowers the price target from $84 to $79.
Analyst Ratings For Sage Therapeutics
Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings within the last quarter:
Morgan Stanley Maintains Equal-Weight on Sage Therapeutics, Lowers Price Target to $78
Morgan Stanley analyst Matthew Harrison maintains Sage Therapeutics (NASDAQ:SAGE) with a Equal-Weight and lowers the price target from $81 to $78.
Rising Oil Prices and Yields Makes Market Navigation More Complex
Bitcoin (/BTC) topped $50,000 this morning for the first since May, but traders may be more focused on oil prices and yields. Crude oil (/CL) is continuing its rise as futures traded more than 1% higher before the market open.
Stifel Maintains Buy on Sage Therapeutics, Lowers Price Target to $75
Stifel analyst Paul Matteis maintains Sage Therapeutics (NASDAQ:SAGE) with a Buy and lowers the price target from $95 to $75.
Needham Initiates Coverage On Sage Therapeutics with Buy Rating, Announces Price Target of $84
Needham analyst Ami Fadia initiates coverage on Sage Therapeutics (NASDAQ:SAGE) with a Buy rating and announces Price Target of $84.
Why Sage Therapeutics Shares Are Trading Higher Today
Sage Therapeutics (NASDAQ:SAGE) shares are trading higher after the company announced it received Fast Track Designation for SAGE-718 or the treatment of Huntington's disease.
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 14)